Nasdaq · CIK 0001535955
LPCN Lipocine Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $1.72 on Oct 9, 2026, 0% from the 52-week low and -85% from the high.
Last 90 days
Net insider value
+$82k
more bought than sold
Buys
2
$82k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
7
with a Form 4 at this company
Price and insider trades, last year
LPCNOct 9, 2026 · close 1.72
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Lipocine Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | John W. Higuchi director buy | $55k 25,007 shares | +12% | +11% from low-81% from high | |
| 41Moderate | John W. Higuchi director buy | $27k 12,561 shares | +6% | +8% from low-81% from high |
Transactions
The last 13 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | John W. Higuchi director | POpen-market purchase Common stock | +9,037 | $2.15 | $19k | 225,395 | 12 d ago |
| Sep 30, 2026 | John W. Higuchi director | POpen-market purchase Common stock | +15,970 | $2.23 | $36k | 241,365 | 12 d ago |
| Sep 28, 2026 | John W. Higuchi director | POpen-market purchase Common stock | +12,561 | $2.16 | $27k | 216,358 | 13 d ago |
| Jan 2, 2026 | Mahesh V. Patel Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $8.00 | $200k | 182,668 | Jan 5, 2026 |
| Dec 18, 2025 | Krista Fogarty Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +20,786 | $4.20 | $87k | 40,146 | Dec 19, 2025 |
| Dec 18, 2025 | Mahesh V. Patel Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +8,629 | $4.20 | $36k | 157,668 | Dec 19, 2025 |
| Jun 4, 2025 | Jeffrey Arvin Fink director | AGrant or award Common Stock (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 11,526 | Jun 5, 2025 |
| Jun 4, 2025 | John W. Higuchi director | AGrant or award Common Stock (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 11,526 | Jun 5, 2025 |
| Jun 4, 2025 | Jill M. Jene director | AGrant or award Stock Option (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 7,174 | Jun 5, 2025 |
| Jun 4, 2025 | Richard Dana Ono director | AGrant or award Common Stock (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 11,526 | Jun 5, 2025 |
| Jun 4, 2025 | Spyros Papapetropoulos director | AGrant or award Stock Option (Right to Buy)derivative | +1,764 | $3.20 | $5,645 | 7,174 | Jun 5, 2025 |
| Dec 23, 2024 | Krista Fogarty Principal Accounting Officer | AGrant or award Stock Option (Right to Buy)derivative | +5,943 | $4.80 | $29k | 19,460 | Dec 30, 2024 |
| Dec 23, 2024 | Mahesh V. Patel Chief Executive Officer | AGrant or award Stock Option (Right to Buy)derivative | +26,691 | $4.80 | $128k | 149,039 | Dec 30, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Jeffrey Arvin Finkdirector
- Krista FogartyPrincipal Accounting Officer
- John W. Higuchidirector
- Jill M. Jenedirector
- Richard Dana Onodirector
- Spyros Papapetropoulosdirector, ceo, president, officer
- Mahesh V. PatelChief Executive Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.